The Future of the Lipid Panel: An NLA Expert Discussion

1.75 CME
1.70 CNE
0 MINS
$0 FEE
SAVE

ACTIVITY FORMAT
Activity Type: Application

RELEASE DATE: April 19, 2017
EXPIRATION DATE: April 18, 2018
FEE: There is no fee for this activity.
Estimated Time to Complete the Activity: 1 hour, 45 minutes

TARGET AUDIENCE
Lipidologists, Lipid Specialists, Cardiologists, Endocrinologists, Internists, Nephrologists, Primary Care Physicians, Family Practitioners, PhDs, Physicians Assistants, Cardiovascular Nurses, Registered Nurses, Nurse Practitioners, Pharmacists, and Dietitians.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, all participants should be able to:

  • Apply guidelines into daily practice to help patients reach goals;
  • Review the current controversies for the use of non-HDL and LDL in risk assessment;
  • Review apolipoprotein B (Apo B) as a universal target of atherosclerosis prevention;
  • Discuss the significance of triglyceride abnormalities in ASCVD risk prediction;
  • Evaluate clinical scenarios where fasting lipid profile testing is necessary;
  • Evaluate the appropriate use of Direct LDL-C Calculation and Friedewald Formula for LDL-C measurement and goal attainment in patients;
  • Appraise treatment recommendations and evidence for lipid lowering therapies;
  • Outline current approaches to global CV risk assessment;
  • Compare and contrast the effectiveness of available risk assessment guidelines;
  • Formulate a treatment plan for patients based on results of lipid panel testing;
  • Identify patients who may benefit from genetic testing based on results of lipid panel test results;
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

CRITERIA FOR SUCCESS
In order to receive credit for this enduring program, participants must answer each question and receive a minimum score of 30% on the posttest, review the ensuing critiques and evaluate the activity. A statement of credit will be available upon completion of an evaluation form. If you have questions about this CME/CE activity, please contact the NLA at cme@lipid.org, or PIM at www.pimed.com.

For Pharmacists: Upon successfully completing the post-test with a score of 30% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

COMMERCIAL SUPPORT
This educational activity is supported by an educational grant from Quest Diagnostics, Inc.

CREDIT DESIGNATION

Jointly Accredited ProviderCME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Postgraduate Institute for Medicine CE Credit provided by Postgraduate Institute for Medicine

  

Pharmacists

ACPE

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number 0809-9999-17-596-H01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
This educational activity for 1.7 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

For the advanced practice nurse, this activity has 1.0 contact hours of pharmacotherapy content.

W. Virgil Brown, MD, FNLA
Charles Howard Candler Professor Emeritus
Emory University School of Medicine
Atlanta, GA

Yehuda Handelsman, MD, FACP, FACE, FNLA
Medical Director & Principal Investigator
Metabolic Institute of America
Tarzana, CA

Seth S. Martin, MD, MHS
Associate Director, Lipid Clinic
Assistant Professor of Medicine
Johns Hopkins
Baltimore, MD

Pamela B. Morris, MD, FNLA
Director, Preventive Cardiology
Co‚ÄźDirector, Women’s Heart Care
Medical University of South Carolina
Charleston, SC

DISCLOSURES
W. Virgil Brown, MD, FNLA

Consultant: Akcea, Amgen, AstraZeneca, Esperion, Genzyme/sanofi

Yehuda Handelsman, MD, FNLA
Associate Editor- Journal of Diabetes
Consultant- Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer- Ingelheim, GlaxoSmithKline, Janssen, Merck & Co., Inc., Novo Nordisk, Regeneron, Sanofi
Contracted Research- Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer- Ingelheim, Esperion Therapeutics, Grifols USA, GlaxoSmithKline, Hanmi Pharmaceuticals, Intarcia Therapeutics, Inc., Lexicon, Merck & Co., Inc., Novo Nordisk, Sanofi
Speaker- Amarin, Amgen, AstraZeneca, Boehringer- Ingelheim/ Lilly, Janssen, Novo Nordisk, Regeneron, Sanofi

Seth S. Martin, MD
Advisory Board- Quest Diagnostics, Sanofi/ Regeneron
Contracted Research- Aetna Foundation, Apple, Google
Intellectuall Property Rights- Pending Patent

Pamela B. Morris, MD, FACC, FACP, FACPM, FAHA, FNLA
Advisory Board- Aegerion Pharmaceuticals, AstraZeneca, Regeneron/ sanofi-aventis

NLA staff has nothing to disclose.

PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.

TECHNOLOGY REQUIREMENTS
This program requires the following:

  • An Apple Macintosh or Windows PC Computer with a sound card and speakers for the audio portion of the program.
  • A modern web browser such as Microsoft Edge, Firefox, Chrome or Safari that has been updated within the last 4-6 months.
  • This program requires that your browser allows website cookies and javascript is enabled. This will be the default in most cases.

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.